Search results
Author(s):
Marc P Allard-Ratick
,
Pratik Sandesara
,
Arshed A Quyyumi
,
et al
Added:
3 years ago
Historically, HDL cholesterol (HDL-C) has been inversely associated with adfverse cardiovascular outcomes such as MI, stroke, and cardiovascular death.1–3 This led to widespread belief that HDL-C, in addition to LDL cholesterol (LDL-C), was a modifiable risk factor for cardiovascular disease.
However, efforts to increase HDL-C in high-risk patients with well-controlled LDL-C values have not…
View more
Added:
3 years ago
Dr Shao Hui (University of Florida, Florida, US) discusses the rationale and methods behind a Bayesian interpretation on whether intensive glycaemic control can reduce major adverse cardiovascular events (MACE) using data in long-term clinical trials (e.g. ACCORD and VADT).
Questions:
1. What is the rationale behind this analysis?
2. What were the methods of this analysis?
3. What were your…
View more
Author(s):
Aruna D Pradhan
,
Gurleen Kaur
Added:
1 year ago
AHA 22 - Dr Gurleen Kaur, Director of the CardioNerds Internship(Brigham and Women's Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Aruna Pradhan (Brigham and Women's Hospital, US), study director of the PROMINENT trial (NCT03071692)on the late-breaking data from AHA 2022.
PROMINENT was a multicenter randomized trial aiming to…
View more
Cardiac Markers—Facilitating Diagnosis and Exclusion of Patients with Acute Coronary Syndrome
Author(s):
Judd E Hollander
Added:
3 years ago
Article
Author(s):
Despoina-Rafailia Benetou
,
Panayotis K Vlachakis
,
Charalampos Varlamos
,
et al
Added:
2 years ago
Author(s):
Paul M Ridker
Added:
5 years ago
Prof Paul M Ridker (Brigham and Women’s Hospital, Boston, US) discusses The Cardiovascular Inflammation Reduction Trial (CIRT) - Low Dose Methotrexate for the Prevention of Atherosclerotic Events.Filmed on site at AHA 2018 by Radcliffe Cardiology.
View more
Author(s):
Harriette Van Spall
,
Steven E Nissen
Added:
1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) to have a deep dive into the practice-changing CLEAR-Outcomes trial (NCT02993406).The Phase 3 CLEAR-Outcomes trial was conducted to evaluate the impact of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular…
View more
Author(s):
Ziad A Ali
Added:
7 months ago
ESC 2023 — Dr Ziad Ali (DeMatteis St Francis, US) joins us to discuss the findings from the ILUMIEN IV clinical trial (NCT03507777).
ILUMIEN IV (Abbott Medical Devices)is a prospective, single-blind clinical trial aiming to compare optical coherence tomography (OCT) to an angiography-guided stent implantation strategy. The trial investigated which method achieved a larger post-percutaneous…
View more
Cardiac Markers—Facilitating Diagnosis and Exclusion of Patients with Acute Coronary Syndrome
Author(s):
Judd E Hollander
Added:
3 years ago
Article
Author(s):
Krzysztof Pujdak
,
Jan Kähler
,
Marc Werner
Added:
3 years ago
Significant stenosis of the left main (LM) coronary artery is observed in 7% of coronary angiographies.1 Coronary artery bypass grafting has traditionally been the treatment of choice. In recent years, percutaneous coronary intervention (PCI) has evolved as an alternative, especially for low and intermediate SYNTAX score patients.2 However, during PCI of bifurcation lesions, approximately 50% of…
View more